Precision approaches for cholangiocarcinoma: progress in clinical trials and beyond-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Precision approaches for cholangiocarcinoma: progress in clinical trials and beyond

Published:2022-01-07 Issue: Volume: Page:1-7
ISSN:1354-3784
Container-title:Expert Opinion on Investigational Drugs
language:en
Short-container-title:Expert Opinion on Investigational Drugs

Author:

Uson Junior Pedro Luiz Serrano¹²,Borad Mitesh J¹³⁴⁵

Affiliation:

1. Division of Hematology & Oncology, Department of Medicine, Mayo Clinic, Scottsdale, Arizona, USA

2. Center for Personalized Medicine, Hospital Israelita Albert Einstein, São Paulo, Brazil

3. Center for Individualized Medicine, Mayo Clinic, Rochester, Minnesota, USA

4. Department of Molecular Medicine, Rochester, Minnesota, USA

5. Mayo Clinic Cancer Center, Mayo Clinic, Phoenix, Arizona, USA

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/13543784.2022.2017882

Reference59 articles.

1. Biliary tract cancer

2. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

3. Key challenges for drugs in clinical development for cholangiocarcinoma

4. Recent advances in understanding cholangiocarcinoma

5. Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mutation-based therapies for intrahepatic cholangiocarcinoma: new options on the horizon;Hepatoma Research;2024-01-12

2. Clinical Utility of Ivosidenib in the Treatment of IDH1-Mutant Cholangiocarcinoma: Evidence To Date;Cancer Management and Research;2023-09

3. A drug safety evaluation of pemigatinib for advanced cholangiocarcinoma;Expert Opinion on Drug Safety;2023-06-26

4. Moving beyond single-agent checkpoint inhibition in biliary tract cancers: what is the next frontier?;Immunotherapy;2023-05

5. Guanine nucleotide exchange factor T exerts the cancer-promoting function in cholangiocarcinoma by enhancing the Wnt-GSK-3β-β-catenin cascade via regulation of Rac1/Cdc42;Toxicology and Applied Pharmacology;2023-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3